The patient with small cell lung cancer has been saved, and the new treatment has significant effects

• by EVOMT
• 2017-06-05

　　Small cell lung cancer accounts for 10% to 25% of lung cancer. Small cell lung cancer is characterized by rapid growth, rapid metastasis, high malignancy, and susceptibility to early metastasis, with an average natural survival period of only 3-6 months. Currently, there are no standard targeted treatment drugs for small cell lung cancer. Although it is sensitive to chemotherapy and radiotherapy, and has a high initial remission rate, it is extremely prone to secondary drug resistance and relapse. Currently, conventional treatment is mainly systemic chemotherapy, but progress is slow and prognosis is extremely poor. It is gratifying that, With the continuous progress of medicine, there have been certain breakthroughs in the research and development of new drugs and technologies for small cell lung cancer in recent years. A45 dynamic immunotherapy, a non invasive tumor treatment technology in the clinical stage, has significant therapeutic effects on small cell lung cancer

　　Patient male, 80 years old, small cell lung cancer

　　Mr. Xue's father, who is already 80 years old, was diagnosed with small cell lung cancer on July 20th, 2013, with multiple mediastinal lymph node metastases and pleural effusion. Due to his age and physical fitness, he was not suitable for surgical resection. After blindly taking the targeted drug Yiruisha for 3 months, he developed drug resistance. After treatment with A45, the patient's primary and metastaticfile lesions basically disappeared. The left two images show CT and PET CT images before tumor treatment, while the right two images show images after treatment. The primary and lymph node metastaticfile lesions basically disappeared, The pleural effusion has subsided and the patient's quality of life is currently good

　　The two images on the left show CT and PET CT images before treatment of the tumor, while the two images on the right show images after treatment. The primary lesions and lymph node metastases have basically disappeared, and pleural effusion has subsided. Currently, the patient's quality of life is good

　　According to the introduction of the International Journal of Medical Physics, A45 tumor treatment technology is fully known as Radiodynamic Therapy (RDT) in medicine. It is a minimally invasive treatment method for tumors combined with medicine and machinery. A45 tumor treatment technology has many advantages such as good non-invasive, selective, strong eradication, low toxicity, and repeatable treatment, and is widely recognized by the international medical community

　　Due to its innovative therapeutic mechanism and significant clinical effects, the FCC Cancer Center of the United States introduced this device in May 2016 to conduct clinical trials, becoming the first cancer center in the United States to test a new method of cancer treatment - radiodynamic therapy